Dare Bioscience, Inc. Earnings Recaps
Q1 2026
May 15, 2026
Dare Bioscience's stock edged up modestly by 0.7% following Q1 2026 results, reflecting a neutral market reaction to updates on its women's health product pipeline and commercial strategy without significant surprises in guidance or margins.
Key takeaways
- Focus remains on commercialization through 503B compounding and advancing proprietary, FDA-regulated women's health products.
- Positive clinician reception for DARE to PLAY at ACOG indicates strong interest from OB/GYNs and sexual health specialists, signaling potential demand growth.
- The company continues to emphasize building a diversified pipeline exclusively targeting women’s health conditions, aiming for recurring revenue via FDA-approved products.
- No explicit guidance changes or margin pressures were noted that would cause material stock movement; market reaction suggests results were broadly in line with expectations.
- The dual-path approach balancing compounding and branded consumer products remains central to execution and capital allocation.
Q3 2025
Nov 14, 2025
Daré Bioscience demonstrated strong momentum in Q3 2025, advancing its dual path strategy in women's health while gearing up for the launch of its sildenafil cream, DARE to PLAY, through 503B compounding.
Key takeaways
- Anticipated launch of DARE to PLAY Sildenafil Cream by December 2025 marks a significant milestone in women's sexual health, utilizing a 503B outsourcing facility.
- Ongoing advancement of clinical programs supported by grant funding, targeting key areas such as contraception and HPV, broadens the company’s innovation pipeline.
- Strategy focuses on bridging gaps in women's health by leveraging partnerships and non-dilutive capital, enhancing market reach and operational efficiency.
- CEO Sabrina Johnson emphasized the importance of addressing real-world needs and accelerating the transition from discovery to product availability for women's health solutions.